Mr. Dean Burns reports

OCUMETICS ACHIEVES HISTORIC FIRST: ACCOMMODATING INTRAOCULAR LENS SUCCESSFULLY IMPLANTED IN HUMAN PATIENTS

Ocumetics Technology Corp. has made a monumental achievement in its mission to revolutionize vision correction: the successful implantation of its groundbreaking accommodating intraocular lens in human subjects.

"This is a moment of immense pride for our team and everyone who has believed in Ocumetics from the beginning," said Dean Burns, president and chief executive officer of Ocumetics. "For nearly two decades, we've been focused on a bold vision, one that many thought was out of reach. Our scientists, engineers, clinical advisers and partners have poured their hearts into this innovation. Today, we celebrate this success, but we know the work is far from done. There are millions of people waiting for us to get the Ocumetics lens to market, and we are more driven than ever to bring this solution to the world."

This achievement marks a major inflection point in the company's 18-year journey, one defined by relentless innovation, determination and belief in the possibility of restoring dynamic vision. The procedures were completed without complications. Early postoperative results will be available in several weeks, and continuing study results will be released over several months as they become available.

"The Ocumetics accommodating intraocular lens has the potential to reshape the global standard of care first for cataract and, eventually, presbyopia patients," added Mr. Burns. "This milestone reinforces Ocumetics's position as a leader in the next generation of ophthalmic innovation. With aging populations around the globe demanding better vision solutions, the potential impact of the Ocumetics lens is profound."

Unlike traditional monofocal or multifocal intraocular lenses, the Ocumetics lens is designed to work with the natural movements of the eye, potentially restoring the ability to see both distant and near objects clearly without glasses or contacts following cataract surgery.

The company will continue its first-in-human clinical trial program, with additional implantations scheduled over the coming months. Each step brings Ocumetics closer to validating the safety and performance of the Ocumetics lens, paving the way for regulatory approvals and broader clinical use.

Investors, partners and medical professionals are encouraged to follow the company's updates as the clinical trial progresses.

About Ocumetics Technology Corp.

Ocumetics is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

Ocumetics is in the preclinical study phase of a game-changing technology for the ophthalmic industry. Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye, potentially to eliminate the need for corrective lenses. It is designed to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.

We seek Safe Harbor.